Biora Therapeutics, Inc. BIORQ
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 4.00K | 18.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 4.00K | 18.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 4.00K | 18.00K |
| SG&A Expenses | -- | -- | -- | 37.31M | 38.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 67.15M | 67.59M |
| Operating Income | -- | -- | -- | -67.14M | -67.58M |
| Income Before Tax | -- | -- | -- | -124.42M | -121.91M |
| Income Tax Expenses | -- | -- | -- | -90.00K | 264.00K |
| Earnings from Continuing Operations | -- | -- | -- | -124.33 | -122.17 |
| Earnings from Discontinued Operations | -- | -- | -- | 219.00K | -253.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -124.12M | -122.42M |
| EBIT | -- | -- | -- | -67.14M | -67.58M |
| EBITDA | -- | -- | -- | -66.58M | -66.98M |
| EPS Basic | -- | -- | -- | -85.66 | -95.88 |
| Normalized Basic EPS | -- | -- | -- | -31.42 | -35.30 |
| EPS Diluted | -- | -- | -- | -85.70 | -95.94 |
| Normalized Diluted EPS | -- | -- | -- | -31.42 | -35.30 |
| Average Basic Shares Outstanding | -- | -- | -- | 6.30M | 4.65M |
| Average Diluted Shares Outstanding | -- | -- | -- | 6.30M | 4.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |